Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in adults with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD).
Epistemonikos ID: cb3c3a60fe33094c57a47858ebd3c76cf7a02f3a
First added on: May 12, 2024